Trending News

Influenza virus
#Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines #National Institute of Allergy and Infectious Diseases #Phase I trial

mRNA universal influenza vaccine enters clinical trials

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase I trial will test the experimental vaccine,… Read More

#News #Trending News

CAR-T therapy
#Blood cancer #CAR-T #Cell therapy #Gilead Sciences #Kite Pharma #National Institute for Health and Care Excellence (NICE) #Oncology

UK’s NICE expands use of CAR-T cell therapy for blood cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended additional uses for two CAR-T therapies from Gilead Sciences/Kite, as part of the Cancer Drugs Fund (CDF). Yescarta (axicabtagene ciloleucel: axi-cel) has been recommended by NICE for the treatment of eligible adult patients with diffuse large B cell… Read More

#News #Regulatory #Trending News

Lottery
#EFPIA #Europe #Marketing approval authorisation #Regulatory

EFPIA report highlights Europe’s medicines lottery

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a series of reports about the availability of new medicines throughout Europe. EFPIA’s 2022 Patient WAIT Indicator tracks the availability of new medicines and length of time it takes patients to get them in 37 countries in the EU… Read More

#News #Regulatory #Trending News

The microbiome
#Cancer research #Gut microbiome #Harvard Medical School #Immunotherapy #Oncology #T cell activation

Gut microbes alter the body’s response to immunotherapy

New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. The findings could inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with… Read More

#Cancer Research #News #Trending News

Scientist in laboratory
#AACR 2023 #Cancer research #Clinical trials #Immunotherapy #Oncology #Rare cancers

Trial results suggest new approaches to treat rare cancers

The AACR Annual Meeting’s second clinical trials plenary session, ‘Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents’, highlighted promising studies that suggest new treatment approaches for rare cancers. First Hippo-YAP pathway inhibitor shows success in advanced solid tumours Timothy A Yap reported on a study… Read More

#Cancer Research #News #Trending News

Gene sequence
#AACR 2023 #Cancer research #Gene mutation #Genetics / genomics #Oncology #Whole genome sequencing

Exome sequencing proves current cancer risk testing is inadequate

Exome sequencing correctly identified individuals with cancer predisposition syndromes who would have been missed by current screening guidelines, according to results from the Tapestry clinical trial. Data presented at the AACR Annual Meeting 2023 showed that among individuals who consented to whole-exome sequencing and were identified… Read More

#Cancer Research #News #Trending News

Histology slides
#AACR 2023 #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Machine learning #Oncology

AI can predict the risk of distant recurrence in endometrial cancer

An investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant recurrence in patients with endometrial cancer, according to findings presented at the AACR Annual Meeting 2023. Endometrial cancer is the most common type of uterine cancer. While patients with early-stage uterine… Read More

#Cancer Research #News #Trending News

Myeloma cells
#AACR 2023 #Antibody #Cancer research #Immunotherapy #Myeloma #Oncology #T cell activation

Bispecific antibody has 90% response rate in multiple myeloma

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual… Read More

#Cancer Research #News #Trending News

Genetics
#AACR 2023 #Cancer research #Colorectal cancer #Genetics / genomics #Oncology

Patients of African heritage have fewer actionable mutations

Genomic profiling of patients who were treated for colorectal cancer showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry. These patients were also less likely to qualify for treatment with immunotherapy, according to data presented at the AACR Annual Meeting… Read More

#Cancer Research #News #Trending News

Lung cancer
#AACR 2023 #Cancer research #Cancer treatment #Lung cancer #Oncology #Phase III trial

Therapy represents ‘new treatment paradigm’ for lung cancer

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN… Read More

#Cancer Research #News #Trending News

#AACR 2023 #Cancer research #Cancer vaccine #mRNA #mRNA-based vaccines #Oncology

Personalised mRNA cancer vaccine prolongs survival in melanoma

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb… Read More

#Cancer Research #News #Trending News

Malaria vaccine
#Africa #Immunology / Virology & Vaccines #Malaria #Regulatory #Serum Institute of India #University of Oxford #Vaccines

Ghana vaccine approval a ‘critical step’ in combatting malaria

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. R21/Matrix-M was developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SIIPL), leveraging Novavax’s… Read More

#News #Regulatory #Trending News

World Parkinson's Day
#Drug development #Drug discovery #Neurodegenerative disorders #Parkinson's

World Parkinson’s Day: New drug research

It is World Parkinson’s Day (11 April), raising awareness of the fastest growing neurological condition in the world. There is currently no cure, and although there are therapeutics to manage the symptoms, these usually bring side-effects, and so there is still need for new therapeutic options. Here, we take a… Read More

#Exclusive Content #Trending News